VitaNova Life Sciences (VNOV) Receivables (2024 - 2026)

VitaNova Life Sciences' Receivables history runs 3 years deep, the most recent figure standing at $832132.0 for Q1 2026.

• Quarterly Receivables changed N/A year-over-year to $832132.0 in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $832132.0 (changed N/A YoY) and the FY2025 annual result came in at $964883.0, up 109.36% from the prior year.
• Receivables was $832132.0 for Q1 2026 at VitaNova Life Sciences, down from $896120.0 in the prior quarter.
• Across five years, Receivables topped out at $1.0 million in Q3 2025 and bottomed at -$168480.0 in Q4 2024.
• A 3-year average of $631482.5 and a median of $793051.5 in 2025 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 631.89% in 2025, while the deepest fall reached 63.6% in 2025.
• VitaNova Life Sciences' Receivables stood at -$168480.0 in 2024, then jumped by 631.89% to $896120.0 in 2025, then decreased by 7.14% to $832132.0 in 2026.
• Business Quant data shows VNOV's Receivables at $832132.0 in Q1 2026, $896120.0 in Q4 2025, and $1.0 million in Q3 2025.